Affiliate disclosure: some links on this page are affiliate links and may earn us a commission at no extra cost to you — it never affects our rankings or reviews.
Guide · Medicare · United States
Does Medicare cover Wegovy?
Yes, in some cases: from July 1, 2026 Medicare's GLP-1 Bridge covers Wegovy, the injection and the tablet, for $50 a month if you meet the criteria. The Bridge runs to December 31, 2027 and needs prior authorization from your prescriber; separately, Part D plans may cover Wegovy for cardiovascular risk reduction or MASH, which are not Bridge uses.
Every fact on this page carries its source and date; we read them on October 30, 2026. This is general information, not advice about your plan or your health: a clinician decides whether a medicine is right for you, and Medicare or your plan decides coverage.
Who is eligible for the Medicare GLP-1 Bridge
The Medicare GLP-1 Bridge is a short-term CMS demonstration running from July 1, 2026 to December 31, 2027. It covers Foundayo (tablet), Wegovy (injection or tablet), Zepbound KwikPen. To use the Bridge you must be 18 or older and, at the start of treatment, have one of the following. The medicine must be prescribed for weight reduction and maintenance, alongside changes to diet and activity.
- A BMI of 35 or higher.
- A BMI of 30 or higher with heart failure with preserved ejection fraction (HFpEF), uncontrolled high blood pressure (systolic above 140 or diastolic above 90 despite two blood pressure medicines) or chronic kidney disease stage 3a or later.
- A BMI of 27 or higher with prediabetes, a previous heart attack, a previous stroke or symptomatic peripheral artery disease.
The Bridge is not for people with type 2 diabetes, people with moderate-to-severe obstructive sleep apnea, people with fatty liver disease (MASH): they use their Part D plan, which may already cover a GLP-1 for those conditions. Nor is it for people already getting a GLP-1 (semaglutide, tirzepatide, orforglipron, dulaglutide or liraglutide) through Part D, or people using a GLP-1 for cardiovascular risk reduction, which the CMS sponsor FAQ lists as a Part D-coverable use.
You can use it with a standalone Part D plan (PDP), a Medicare Advantage plan with drug coverage (HMO, HMO-POS, local or regional PPO), a Special Needs Plan, an employer group waiver plan (EGWP) or LI NET. It is not available if your only coverage is PFFS, a section 1876 cost plan, a section 1833 prepayment plan, PACE, a fallback plan or a religious fraternal plan, unless you also have a standalone Part D plan.
Sources: CMS: Medicare GLP-1 Bridge (page last modified July 13, 2026); CMS prescriber fact sheet (No. 12235) (June 2026); Medicare.gov fact sheet: Medicare GLP-1 Bridge (CMS Product No. 12234) (June 2026); CMS: Medicare GLP-1 Bridge expectations and FAQs for Part D sponsors (June 10, 2026); Medicare.gov: Weight loss drugs (no page date). Read October 30, 2026.
How to get it: prior authorization
Your prescriber starts the process; you cannot apply on your own. In outline:
- Your prescriber sends the prescription with a weight-management diagnosis code and the note "SEND TO BRIDGE FOR WEIGHT MANAGEMENT".
- The Bridge's central processor declines the first claim and asks for prior authorization. Your prescriber submits it electronically or by fax on the CMS form and attests that you meet the criteria.
- A decision comes within 72 hours. There is no formal appeal, but your prescriber can resubmit.
- An approval lasts to December 31, 2027 unless you switch to a different GLP-1. Refills and dose changes need no new prior authorization; switching medicine does.
Sources: CMS prescriber fact sheet (No. 12235) (June 2026); CMS: Medicare GLP-1 Bridge prior authorization form (no page date); Medicare.gov: Weight loss drugs (no page date); Obesity Medicine Association: updates to Medicare coverage of GLP-1 medications (secondary) (updated July 14, 2026). Read October 30, 2026.
What it costs under the Bridge
- You pay $50 a month for a covered medicine.
- The Part D deductible does not apply, and the copay does not count toward your Part D out-of-pocket costs or the out-of-pocket cap.
- Extra Help (the low-income subsidy) does not apply to Bridge drugs, and the Medicare Prescription Payment Plan cannot be used for them.
- Manufacturer coupons and discount programs cannot be applied to Bridge claims.
- Only 28 or 30 day fills are covered, not 60 or 90 day fills.
- Under the Bridge, the manufacturers supply the medicines at a net price of $245 a month; your share is the $50 copay.
People with both Medicare and Medicaid can use the Bridge if they have qualifying Part D coverage, and still pay the full $50, because Extra Help does not apply. Whether a state Medicaid program pays that copay varies by state: Pennsylvania's will not (PHLP, June 26, 2026).
Sources: CMS: Medicare GLP-1 Bridge (page last modified July 13, 2026); CMS: Medicare GLP-1 Bridge expectations and FAQs for Part D sponsors (June 10, 2026); Medicare.gov fact sheet: Medicare GLP-1 Bridge (CMS Product No. 12234) (June 2026); Healthcare Finance News: Medicare launches the GLP-1 Bridge for eligible Part D beneficiaries (no page date); PHLP: New Medicare program to offer limited coverage for GLP-1 weight loss medications (June 26, 2026). Read October 30, 2026.
Which Wegovy is covered
The Medicare.gov fact sheet lists Wegovy as an injection or a tablet. CMS lists products, not doses, so whether the Bridge covers the 7.2 mg dose (Wegovy HD) is not confirmed.
Sources: Medicare.gov fact sheet: Medicare GLP-1 Bridge (CMS Product No. 12234) (June 2026); CMS prescriber fact sheet (No. 12235) (June 2026). Read October 30, 2026.
Wegovy for heart risk or MASH: Part D, not the Bridge
Part D plans can cover Wegovy to reduce cardiovascular risk in people with established heart disease and overweight or obesity (CMS, March 2024), and for noncirrhotic MASH. Coverage depends on your plan's formulary and its prior authorization rules.
The CMS sponsor FAQ lists both as Part D uses that exclude a patient from the Bridge, so if one of them applies to you, Part D is the route.
Sources: Managed Healthcare Executive: Medicaid, Medicare Part D to provide coverage of Wegovy, but not for weight loss (March 22, 2024); CMS: Medicare GLP-1 Bridge expectations and FAQs for Part D sponsors (June 10, 2026). Read October 30, 2026.
Why Part D does not cover Wegovy for weight loss
Part D law excludes drugs "when used for anorexia, weight loss, or weight gain". Wegovy became a Part D drug only for its other approved uses. The Bridge works around the exclusion as a CMS demonstration that sits outside the Part D benefit.
Sources: Congressional Research Service In Focus IF12758 (September 9, 2024); Managed Healthcare Executive: Medicaid, Medicare Part D to provide coverage of Wegovy, but not for weight loss (March 22, 2024); CMS: Medicare GLP-1 Bridge (page last modified July 13, 2026). Read October 30, 2026.
If you are not eligible, or not covered
If you have type 2 diabetes, sleep apnea, fatty liver disease or heart disease, ask your Part D plan what it covers for that condition. The Bridge ends on December 31, 2027. CMS has not said what follows: its page says only that Bridge data may inform a possible BALANCE model in Part D, and KFF (April 23, 2026) says CMS's approach after the Bridge is unknown.
The manufacturer sells Wegovy direct for cash, with a prescription you already hold. We list these prices for information; PCF has no commercial relationship with the manufacturer.
- NovoCare Pharmacy lists the Wegovy pill at $149 a month at the starting dose, checked November 19, 2026. No membership printed, prescription required. NovoCare Pharmacy's page
- NovoCare Pharmacy lists the Wegovy pen at $199 a month at the starting dose ("Offer is for 2 monthly fills through December 31, 2026"; then $349 per month), checked November 19, 2026. No membership printed, prescription required. NovoCare Pharmacy's page
Medicare enrollees can use NovoCare self-pay but must agree not to count the cost toward their Part D deductible or out-of-pocket limit (NovoCare's Ozempic terms). Prices are read daily from each seller's own page; see the brand-name GLP-1 price chart for every seller.
For every cash price, see what Wegovy costs without insurance, from the manufacturer's self-pay price to telehealth programs.
Sources: CMS: Medicare GLP-1 Bridge (page last modified July 13, 2026); KFF: CMS extends Medicare's short-term Bridge program for GLP-1 obesity drug coverage (April 23, 2026); NovoCare: Ozempic self-pay pricing and terms (no page date). Read October 30, 2026.
Frequently asked questions
Does Medicare cover Wegovy for weight loss?
Yes, in some cases. From July 1, 2026 to December 31, 2027, the Medicare GLP-1 Bridge covers Wegovy (injection or tablet) for $50 a month for people with Part D coverage who meet the BMI and health criteria, with prior authorization (CMS; Medicare.gov fact sheet, June 2026).
Who qualifies for Wegovy under the Bridge?
Adults 18 or older with a BMI of 35 or higher; or a BMI of 30 or higher with heart failure with preserved ejection fraction (HFpEF), uncontrolled high blood pressure (systolic above 140 or diastolic above 90 despite two blood pressure medicines) or chronic kidney disease stage 3a or later; or a BMI of 27 or higher with prediabetes, a previous heart attack, a previous stroke or symptomatic peripheral artery disease, prescribed for weight reduction alongside lifestyle changes. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are excluded and use Part D (CMS prescriber fact sheet, June 2026).
How much does Wegovy cost with Medicare?
Under the Bridge, $50 a month. The Part D deductible does not apply, the copay does not count toward your out-of-pocket costs, and Extra Help does not reduce it (CMS, 2026).
Does Medicare cover Wegovy for heart disease?
Part D plans can cover Wegovy for cardiovascular risk reduction in people with established heart disease and overweight or obesity (CMS, March 2024), subject to the plan's formulary. It is not a Bridge use.
Is the Wegovy pill covered?
Yes. The Medicare.gov fact sheet (June 2026) lists Wegovy as an injection or a tablet under the Bridge.
What happens after the Bridge ends?
The Bridge runs to December 31, 2027. CMS has not said what follows, and KFF (April 23, 2026) says its approach after the Bridge is unknown.